Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial.

Date publication

octobre 2018

Journal

American journal of obstetrics and gynecology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VILLENA Isabelle

Tous les auteurs :
Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, Berrebi A, Le Bouar G, Bory JP, Cordier AG, Ville Y, Perrotin F, Jouannic JM, Biquard F, d'Ercole C, Houfflin-Debarge V, Villena I, Thiébaut R,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29870736

Résumé

The efficacy of prophylaxis to prevent prenatal toxoplasmosis transmission is controversial, without any previous randomized clinical trial. In France, spiramycin is usually prescribed for maternal seroconversions. A more potent pyrimethamine + sulfadiazine regimen is used to treat congenital toxoplasmosis and is offered in some countries as prophylaxis.

Mots clés

pregnancy, prenatal diagnosis, pyrimethamine-sulfadiazine, spiramycin, tolerance, toxoplasmosis

Référence

Am J Obstet Gynecol. 2018 10;219(4):386.e1-386.e9